Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital Tract
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a single-center, open-label, single-arm phase II clinical study to exploratory
observe and evaluate the efficacy and safety of anti-PD-1 antibody (Camrelizumab for
Injection) in patients with malignant melanoma of the female genital tract.
Subjects were to have a safety visit 3 days prior to dosing in each treatment cycle after the
study. Imaging was performed every 8 weeks to assess efficacy until radiographic progression,
initiation of new antineoplastic therapy, withdrawal of consent, or subject lost to
follow-up/death.
After the end of treatment, an end-of-treatment visit and a post-treatment safety visit will
also be performed. After the end of treatment, subjects will also be followed up for survival
(every 3 months for years 1 to 2, every 4 months for years 3, every 6 months for years 4 to
5, and annually from year 6) to collect and record the survival status of subjects and
subsequent anti-tumor treatment.